2 A.I CyberSecurity Scoring
02/05/2026
Access Monitoring Plan
Access Monitoring Plan
No incidents recorded for 2TN (2 the Nth) in 2026.
No incidents recorded for 2TN (2 the Nth) in 2026.
No incidents recorded for 2TN (2 the Nth) in 2026.
Viatris Inc. (NASDAQ: VTRS) is a global healthcare company uniquely positioned to bridge the traditional divide between generics and brands, combining the best of both to more holistically address healthcare needs globally. With a mission to empower people worldwide to live healthier at every stage of life, we provide access at scale. In 2022 alone, we supplied high-quality medicines to approximately 1 billion patients around the world. With our exceptionally extensive and diverse portfolio of medicines, a one-of-a-kind global supply chain designed to reach more people when and where they need them, and the scientific expertise to address some of the world’s most enduring health challenges, access takes on deep meaning at Viatris. We have the ability to touch all of life’s moments, from birth to end of life, acute conditions to chronic diseases. We are headquartered in the U.S., with global centers in Pittsburgh, Shanghai and Hyderabad, India Social Media Guidelines: https://newsroom.viatris.com/social-media-community-guidelines Investors: https://investor.viatris.com Corporate Social Responsibility: https://www.viatris.com/sustainability Connect with Viatris Instagram: https://www.instagram.com/viatrisinc X: https://www.x.com/viatrisinc Viatris and our recruiting firms will not ask for sensitive personal information, such as your social security number, date of birth or bank account details via text, email or social media. Additionally, Viatris representatives do not request payment or personal bank information nor send payment to purchase hardware on your own. Viatris.com is the primary source of all company job postings and authorized third-party career websites.
We're a medicine company turning science into healing to make life better for people around the world. It all started nearly 150 years ago with a clear vision from founder Colonel Eli Lilly: "Take what you find here and make it better and better." Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing science to solve some of the world's most significant health challenges. General Information and Guidelines: When you engage with us on LinkedIn, you're agreeing to these Community Guidelines: https://e.lilly/guidelines. If you have questions about a Lilly medicine, contact The Lilly Answers Center at 1-800-Lilly-Rx (1-800-545-5979) Monday through Friday, excluding company holidays.
Novartis is an innovative medicines company. Every day, working to reimagine medicine to improve and extend people’s lives so that patients, healthcare professionals and societies are empowered in the face of serious disease. Our medicines reach more than 250 million people worldwide. Find out more at https://www.novartis.com See our community guidelines: https://go.novartis.social/3Nboxki
This channel is not intended for U.S. and Canadian visitors. Merck operates in the U.S. and Canada as EMD Serono in Healthcare, MilliporeSigma in Life Science and EMD Electronics in Electronics. An unaffiliated and unrelated company, Merck & Co., Inc., Kenilworth, NJ, US holds the rights in the trademark MERCK in the U.S. and Canada. _______________________________ We are Merck, a leading global science and technology company headquartered in Germany. We are curious explorers, courageous pioneers, and ingenious inventors. Our colleagues across the globe love innovating with science and technology to enrich people’s lives with our solutions in Life Science, Healthcare, and Electronics. Together, we dream big and are passionate about caring for our rich mix of people, customers, patients, and the planet. We believe in the positive power of science and technology. It has determined our actions since 1668 and inspires us to continue researching for a future worth living. As a family-owned company with over 350 years of experience, we stand for sustainability, responsibility, and innovative strength. We take pride in being a diverse and inclusive company that values and fosters the talents and abilities of our employees. That's why we are always looking for curious minds that see themselves imagining the unimaginable with us. Work your Magic and join Merck. Legal Disclaimer: www.merckgroup.com/en/legal-disclaimer.html Data Privacy Declaration: www.merckgroup.com/en/privacy-statement
Teva Pharmaceuticals is a leading innovative biopharmaceutical company, enabled by a world-class generics business. For over 120 years, Teva’s commitment has never wavered. From innovating in the fields of neuroscience and immunology to providing complex generic medicines, biosimilars and pharmacy brands worldwide, Teva is dedicated to addressing patients’ needs, now and in the future. At Teva, We Are All In For Better Health. To learn more about how we make it happen, visit www.tevapharm.com. Our community guidelines may be found here: https://www.tevapharm.com/news-and-media/teva-social-media-guidelines/ Please note that adverse effects for any of our products should be reported at: https://www.tevapharm.com/teva-medical-information/report-a-side-effect-form/ Product-specific questions should be directed to Teva or Teva Group subsidiaries in your country. Contact details and Teva's Pharmacovigilance Privacy Policy may be found here: http://www.tevapharm.com/contact_us/
The Menarini Group is a leading international pharmaceutical and diagnostics company, present in 140 countries worldwide, with a turnover of 4,37 Billion euro and more than 17,000 employees. With 9 centers for Research & Development, Menarini’s products are present in the most important therapeutic areas, including cardiology, oncology, gastroenterology, pneumology, infectious diseases, diabetes, and anti-inflammatory/analgesics. The Group’s pharmaceutical production is carried out in its 18 manufacturing plants, which produce over 609 million packets of product a year and distribute them to five continents. Menarini’s pharmaceutical production, in line with the highest quality standards, provides an ongoing contribution to the health of patients all over the world. For further information, please visit www.menarini.com For reading our Netiquette, please visit https://www.menarini.com/en-us/data-privacy/netiquette-of-menarini-group For reading our Privacy Notice for social networks users, please visit https://www.menarini.com/en-us/data-privacy/privacy-notice-for-social-network-users-of-menarini-group
A consumer-led global pharmaceutical company, creating healthy doses of life since 1949. When you operate in an industry like pharmaceuticals, your work goes way beyond creating ‘products for customers’. It is different from any other domain – there lies a higher sense of responsibiliti and a need for utmost integriti in everything you do. As you serve millions of lives, high qualiti standards become a pre-requisite, and safeti of your people and consumers always comes first. All this, while ensuring that each life you touch is treated with respect and digniti. For more than 60 years, Ipca has been a crucial healthcare partner in over 120 countries across the 6 continents. We are a fully-integrated pharmaceutical company that manufactures over 350 formulations and 80 APIs for various therapeutic segments. Today, we are one of the world’s largest manufacturers and suppliers of over a dozen APIs. These are produced from scratch at fully-automated manufacturing facilities, approved by the world’s most discerning drug regulatory authorities like UK-MHRA, EDQM-Europe, and WHO-Geneva, among others. - One of the largest suppliers of these APIs worldwide with manufacturing leadership in over 12 APIs globally - 15 APIs & 11 Formulations manufacturing facility across the globe Leader in DMARDs (Disease Modifying Anti-Rheumatic Drugs) treatment for Rheumatoid Arthritis - Leading brands in Pain, Rheumatology, Antimalarials and Hair care therapy - 4 formulations rank amongst the top 300 brands of IPM as per IQVIA
At Bristol Myers Squibb, we work every day to transform patients’ lives through science. That work inspires some of the most interesting, meaningful, and life-changing careers you’ll experience. Join us and pursue innovative ideas alongside some of the brightest minds in biopharma, collaborating with a team rich in diversity of experiences, and perspectives. We have built a sustainable pipeline of potential therapies and are leveraging translational medicine and data analytics to understand how we can deliver the right medicine to the right patient, at the right time, to achieve the best outcome. Whether in a scientific, business or supporting function, a career at BMS means you’ll be inspired every day to grow and thrive through opportunities that are uncommon in scale and scope. Here, you’ll be on the cutting edge of powerful innovation in oncology, hematology, immunology, cardiovascular disease, and fibrosis, with colleagues united in the mission to help patients. Through the Bristol Myers Squibb Foundation, we also promote health equity and seek to improve health outcomes of populations disproportionately affected by serious diseases and conditions. Our mission is to give new hope to help patients prevail over serious disease – it drives everything we do. Review our Social Media Community Guidelines at: https://www.bms.com/social-media-community-guidelines.html
Lonza is a pioneer and world leader in the CDMO industry, setting the pace with cutting-edge science, smart technology, and lean manufacturing. United by a common purpose, we turn our customers’ breakthrough innovations into viable therapies and manufacture the medicines of tomorrow. Founded in Switzerland in 1897, our company is the first and original CDMO, and today we are more dynamic, agile and forward-focused than ever before. As one of the largest Western CDMOs, we bring together a global team of around 18,500 colleagues across five continents to deliver comprehensive, integrated solutions for our customers' complex needs. For our customers and their patients, we bring quality, safety and reliability to bring life-enhancing and life-saving treatments to market at speed and at scale. For our colleagues, we strive to create a sense of belonging and inclusion where every person can thrive and bring their best.
Latest updates, reports, and threat intel affecting the global network.
In Zephyr's userspace dynamic-objects subsystem, thread_idx_alloc() in kernel/userspace/userspace.c allocated a new thread permission index from the global _thread_idx_map[] bitmap without holding lists_lock. On SMP systems, two user-mode threads invoking the k_object_alloc(K_OBJ_THREAD) syscall concurrently can both observe the same low free bit, perform the same non-atomic RMW to clear it, and return the identical tidx. The two newly created K_OBJ_THREAD objects are then assigned the same thread_id, so the two user threads alias a single bit position in every kernel object's perms[] bitfield: any subsequent grant of access on a kernel object to one thread is implicitly a grant to the other, defeating userspace ACL isolation. A secondary lost-update window between the unlocked &=~BIT() in alloc and the locked |= BIT() in thread_idx_free() can also leak entries from the thread-index pool. The defect is reachable from any user-mode thread via the unrestricted __syscall k_object_alloc and is gated on CONFIG_USERSPACE, CONFIG_DYNAMIC_OBJECTS, and CONFIG_SMP. The flaw was introduced when the per-thread permission index was added in 2018 and is present in every release up to and including v4.4.0. Fixed by holding lists_lock across the bitmap RMW and the permissions clear (and inlining the obj_list traversal that previously took the lock itself).
OpenRemote before 1.26.2 contains an authentication bypass vulnerability in the console registration API that allows unauthenticated attackers to update existing console assets by supplying a known asset identifier. Attackers can overwrite push notification tokens and console metadata without authentication or ownership validation, redirecting notifications or denying delivery to legitimate consoles.
SiYuan before v3.7.2 contains a missing authorization vulnerability in the POST /mcp kernel endpoint, which is gated only by a general auth check (model.CheckAuth) with no admin-role or read-only enforcement. This exposes 31 MCP tools, including a file tool with list/read/write/delete/rename/copy actions across the entire workspace. When the Publish server is enabled in anonymous mode (Conf.Publish.Enable=true and Conf.Publish.Auth.Enable=false), the Publish reverse proxy attaches an anonymous RoleReader JWT to proxied requests, allowing a remote unauthenticated attacker to reach /mcp. The attacker can read conf/conf.json to extract accessAuthCode, api.token, and cookieKey in plaintext, write arbitrary files in the workspace, and plant a plugin into data/plugins/ that executes with nodeIntegration:true and no contextIsolation on the next desktop launch, leading to administrator takeover.
ImageMagick before 7.1.2-27 contains a memory leak vulnerability in the magick command-line interface when invalid options are provided. Attackers can trigger memory exhaustion by repeatedly supplying malformed command-line arguments to consume system resources.
In the Linux kernel, the following vulnerability has been resolved: crypto: qat - remove unused character device and IOCTLs The QAT driver exposes a character device (qat_adf_ctl) with IOCTLs for device configuration, start, stop, status query and enumeration. These IOCTLs are not part of any public uAPI header and have no known in-tree or out-of-tree users. Device lifecycle is already managed via sysfs. The ioctl interface also increases the attack surface and is the subject of a number of bug reports. Remove the character device, the IOCTL definitions, and the related data structures (adf_dev_status_info, adf_user_cfg_key_val, adf_user_cfg_section, adf_user_cfg_ctl_data). Drop the now-unused adf_cfg_user.h header and strip adf_ctl_drv.c down to the minimal module_init/module_exit hooks for workqueue, AER, and crypto/compression algorithm registration. Clean up leftover dead code that was only reachable from the removed IOCTL paths: adf_cfg_del_all(), adf_devmgr_verify_id(), adf_devmgr_get_num_dev(), adf_devmgr_get_dev_by_id(), adf_get_vf_real_id() and the unused ADF_CFG macros. Additionally, drop the entry associated to QAT IOCTLs in ioctl-number.rst.
curl -i -X GET 'https://api.rankiteo.com/underwriter-getcompany-history?
linkedin_id=axa' -H 'apikey: YOUR_API_KEY_HERE'
Every week, Rankiteo analyzes billions of signals to give organizations a sharper, faster view of emerging risks. With deeper, more actionable intelligence at their fingertips, security teams can outpace threat actors, respond instantly to Zero-Day attacks, and dramatically shrink their risk exposure window.
Rankiteo is a unified scoring and risk platform that analyzes billions of signals weekly to help organizations gain faster, more actionable insights into emerging threats. Empowering teams to outpace adversaries and reduce exposure.